Βιβλιογραφικές αναφορές

1. TECENTRIQ^® Περίληψη χαρακτηριστικών του προιόντος.
2. Rittmeyer A, Barlesi F, Waterkamp D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.
3. Satouchi et al., OA 17.07, IASLC, 18th World Conference on lung cancer.
4. Pillai R et al; Cancer 2018;124:271-7.
5. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580-6587.
6. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567.

PR/ATEZ/1704/0013a (replace with local ZINC number)